Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.

Diabetes, Obesity & Metabolism
Wathik AlsalimBo Ahrén

Abstract

Previous studies have shown that dipeptidyl peptidase (DPP)-4 inhibition lowers glucagon levels whereas sodium-glucose co-transporter 2 (SGLT-2) inhibition increases them. This study evaluated the extent of these opposite effects in a direct comparative head-to-head study. In a single-centre, randomized study with a cross-over design, 28 metformin-treated patients with type 2 diabetes (T2D) (mean age, 63 years; baseline HbA1c, 6.8%) were treated with vildagliptin (50 mg twice daily) or dapagliflozin (10 mg once daily) for 2 weeks, with a 4-week wash-out period between the two separate treatments. After each treatment period, a meal test was undertaken, with measurements of islet and incretin hormones and 4-hour area under the curve (AUC) levels were estimated. Fasting glucagon (35.6 ± 2.5 vs 39.4 ± 3.4 pmoL/L; P = .032) and postprandial glucagon (4-hour AUCglucagon , 32.1 ± 2.3 vs 37.5 ± 2.7 nmoL/L min; P = .001) were ~15% lower after vildagliptin compared to dapagliflozin treatment. This was associated with stronger early (15 minute) C-peptide response and higher 4-hour AUCC-peptide (P < .010), higher 4-hour AUC of the intact form of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (P < .0...Continue Reading

References

Apr 1, 1982·Diabetologia·B Ahrén, I Lundquist
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Bo AhrénAnja Schweizer
Dec 29, 2006·Journal of Clinical Pharmacology·Yan-Ling HeMonica Ligueros-Saylan
Sep 13, 2008·Molecular and Cellular Endocrinology·Jens Juul HolstCarolyn F Deacon
Jan 29, 2009·The Journal of Clinical Endocrinology and Metabolism·Bo AhrénJames E Foley
Apr 22, 2011·Diabetes, Obesity & Metabolism·B AhrénJ E Foley
May 28, 2011·Diabetes, Obesity & Metabolism·J I BaggerT Vilsbøll
Jan 5, 2012·The Journal of Clinical Investigation·Roger H Unger, Alan D Cherrington
Jun 12, 2012·The Journal of Clinical Endocrinology and Metabolism·Elza MuscelliEle Ferrannini
Jan 28, 2014·The Journal of Clinical Investigation·Aurora MerovciRalph A DeFronzo
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Nov 6, 2014·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Lars HansenBoaz Hirshberg
Jun 19, 2015·The Journal of Clinical Endocrinology and Metabolism·Simeon I TaylorKristina I Rother
Jan 1, 2015·Clinical Pharmacology in Drug Development·David PolidoriAlin Stirban
Aug 27, 2016·Diabetes Care·Giuseppe DanieleMuhammad Abdul-Ghani

❮ Previous
Next ❯

Citations

Jul 14, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tomoho NodaMasamitsu Nakazato
May 23, 2021·The Journal of Clinical Endocrinology and Metabolism·Andrea KellyMichael R Rickels
Aug 19, 2021·The Journal of Clinical Endocrinology and Metabolism·Andrea KellyMichael R Rickels

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.